[Invasive aspergillosis in immunocompromised patients]

Area of Science:

• Medical Mycology
• Infectious Diseases
• Immunocompromised Host Research

Context:

• Invasive aspergillosis poses a significant threat to immunocompromised individuals.
• Treatment outcomes and diagnostic challenges were evaluated in a cohort of patients from 2000-2002.
• Fungal infections, particularly invasive aspergillosis, are a concern in patients with weakened immune systems.

Purpose:

• To analyze the treatment results of invasive aspergillosis in immunocompromised patients.
• To assess the efficacy of antifungal therapies and identify factors influencing survival.
• To highlight diagnostic delays and propose improved early detection strategies.

Summary:

• A study of 25 immunocompromised patients with invasive aspergillosis revealed a 52% mortality rate.
• Commonly identified species included Aspergillus Fumigatus (67%).
• Treatment involved Amphotericin B, with some patients switched to liposomal formulations or treated with itraconazole; cure rates were 48%.

Impact:

• The high mortality rate underscores the severity of invasive aspergillosis in this population.
• Delayed fungal detection impacts treatment effectiveness.
• Recommendations include monitoring Aspergillus antigen (galactomannan) and chest CT for early diagnosis in persistent fever cases.